Featured
-
-
News & Views |
Shock and kill
Antiretroviral therapies block HIV replication but they do not eliminate inactive viruses within cells. A clinical trial shows that a drug can revive HIV in patients as a potential first step towards a cure. See Letter p.482
- Steven G. Deeks
-
Outlook |
Animal models: Not close enough
Despite some outstanding drug-development successes, the mouse version of multiple sclerosis has been worryingly unreliable at screening human treatments.
- Jocelyn Rice
-
Outlook |
Progressive multiple sclerosis: The treatment gap
Most new treatments for multiple sclerosis are for patients with the relapsing–remitting form of the disease. Those with the more advanced, progressive type are being left behind.
- Courtney Humphries
-
Article |
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
Synthetic REV-ERB agonists can alter the circadian expression of core clock genes in the hypothalami of mice, which changes the expression of metabolic genes in liver, skeletal muscle and adipose tissue, and results in increased energy expenditure.
- Laura A. Solt
- , Yongjun Wang
- & Thomas P. Burris
-
Letter |
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
The Cancer Cell Line Encyclopedia presents the first results from a large-scale screen of some 947 cancer cell lines with 24 anticancer drugs, with the aim of identifying specific genomic alterations and gene expression profiles associated with selective sensitivity or resistance to potential therapeutic agents.
- Jordi Barretina
- , Giordano Caponigro
- & Levi A. Garraway
-
Article |
Crystal structure of the µ-opioid receptor bound to a morphinan antagonist
The crystal structure of the mouse μ-opioid receptor bound to an antagonist is described, with possible implications for the future development of analgesics.
- Aashish Manglik
- , Andrew C. Kruse
- & Sébastien Granier
-
Letter |
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
In parallel with an ongoing human clinical trial, genetically engineered mouse models of lung cancer with different genetic alterations are treated with chemotherapeutic agents; the results have implications for the clinical trial.
- Zhao Chen
- , Katherine Cheng
- & Kwok-Kin Wong
-
Research Highlights |
Spoilers of chemotherapy
-
News |
Malaria vaccine one step closer to approval
Trial results are promising, but marred by poor efficacy against severe forms of the disease.
- Daniel Cressey
-
News |
German E. coli outbreak leads to drug trial
Timely discovery of new use for expensive drug put to the test.
- Marian Turner
-
News |
Good news for 'good' cholesterol
Positive results inject life into strategy to treat heart disease.
- Alla Katsnelson
-
News Feature |
Schizophrenia: The drug deadlock
The biology is too complicated. Pharma companies are quitting. Where are schizophrenia drugs going to come from?
- Alison Abbott
-
Letter |
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
PLX4032 is a selective inhibitor of the B-RAF protein that has shown promising results in an early clinical trial in melanoma patients with an activating mutation in B-RAF. Now the structure and function of this inhibitor are described. Translational data from a phase I trial show that clinical efficacy requires a substantial degree of inhibition of the ERK pathway downstream of B-RAF. The data also show that BRAF-mutant melanomas are highly dependent on B-RAF activity.
- Gideon Bollag
- , Peter Hirth
- & Keith Nolop
-
Editorial |
Effective approach
The controversy surrounding diabetes drugs highlights the importance of comparative studies.
-
News |
Party drug could ease trauma long term
Pilot studies demonstrate effectiveness of MDMA for post-traumatic stress disorder.
- Lizzie Buchen
Doctors debate safety of starch drips